Filter by
Latest news from EU institutions and bodies (1601)
RSSShowing results 1600 to 1601
This news announcement was updated on 20 November 2025 to correct the list of frequently reported adverse reactions. , EMA has recommended granting a marketing authorisation in the European Union (EU) for Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes in adults and…